Bristol-Myers Squibb Ends Collaboration with Eisai on Farletuzumab Eteribulin
Bristol-Myers Squibb (BMS; NYSE: BMY), a prominent US pharmaceutical company, has decided to terminate its...
ADC / XDC
Innovent Biologics Presents Positive Phase I Results for IBI343 at ESMO GI Congress 2024
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Receives FDA Clinical Trial Approval
Huadong Medicine Co., Ltd (SHE: 000963), a pharmaceutical company based in China, has announced that...
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million...
Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter
Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...
Sichuan Biokin Pharmaceutical Gets NMPA Go-Ahead for BL-M17D1 Solid Tumor Clinical Study
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced...
Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal
Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...
Sichuan Kelun-Biotech Receives NMPA Clearance for SKB518 Clinical Trial in Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...
BioNTech and MediLink’s HER3 ADC BNT326 Faces Partial Clinical Hold in the US
BioNTech SE (NASDAQ: BNTX), a German biotechnology company, and its Chinese co-development partner MediLink Therapeutics...
RemeGen’s Disitamab Vedotin Shows Positive Results in Phase III Trial for HER2 Positive Breast Cancer
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced positive results from...
Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status
Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...
AbbVie’s Telisotuzumab Vedotin Earns Breakthrough Therapy Designation in China for c-Met Positive NSCLC
AbbVie Inc. (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced that...
Alphamab Oncology Partners with ArriVent BioPharma for Global ADC Development and Commercialization
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has entered into a research...
Jiangsu Hengrui’s HER2 Targeted ADC SHR-A1811 Poised to Earn Breakthrough Designation in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Huadong Medicine’s ROR1-Targeting ADC HDM2005 Cleared for Clinical Trials by China’s NMPA
Huadong Medicine Co., Ltd (SHE: 000963), a biopharmaceutical company based in China, has announced that...
Gilead’s Trodelvy Misses Overall Survival Endpoint in Late-Stage Urothelial Cancer Study
Gilead (NASDAQ: GILD) has announced that a late-stage study for its antibody-drug conjugate (ADC) Trodelvy...
Full-Life Technologies Receives FDA Green Light for ²²⁵Ac-FL-020 Clinical Study in mCRPC
Full-Life Technologies Ltd, a globally integrated radiotherapeutics company with a presence in Belgium, Germany, and...
Medilink Therapeutics Partners with BioNTech to Develop ADC Products Using TMALIN Technology
Medilink Therapeutics, based in Suzhou, has entered into another partnership agreement with German biotechnology company...
Jiangsu Hengrui’s SHR-A1921 Anticipated to Gain NMPA Breakthrough Designation for Ovarian Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that its drug candidate SHR-A1921 is...
Chinese Pharma Companies Set to Showcase Cancer Treatments at ASCO 2024
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 31...